Status of the work in August
AOTMiT begins work on the Ministry of Health’s orders in August:
- Padcev (enfortumab vedotin) in the treatment of patients with urothelial cancer
- Crysvita (burosumab) in the treatment of patients with X-linked hypophosphatemia (XLH)
The listed order is available on the AOTMiT Public Information Bulletin.